NASDAQ:XTLB

Xtl Biopharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy XTLB

*Your capital is at risk

$2.82

-0.0300 (-1.05%)

At Close: Jul 31, 2026

XTL Biopharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 14.59M and sold 86.27M XTLB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	14.59M shares
● Sell	86.27M shares
82% Buy Activity Moderate Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Oct 10, 2008 Buy	OPTIONS TO PURCHASE ORDINARY SHARES A-Award	Weiss Michael S Director	Director	3 500 000 Value: $693.0K
Oct 10, 2008 Buy	OPTIONS TO PURCHASE ORDINARY SHARES A-Award	Weiss Michael S Director	Director	3 500 000 Value: $693.0K
Oct 10, 2008 Buy	Options to Purchase Ordinary Shares A-Award	Weiner Ben-zion Director	Director	300 000 Value: $59.4K
Aug 27, 2008 Buy	OPTIONS TO PURCHASE ORDINARY SHARES	Weiner Ben-zion Director	Director	0 Value: $0
Aug 27, 2008 Buy	ORDINARY SHARES	Weiner Ben-zion Director	Director	0 Value: $0
Aug 27, 2008 Buy	ORDINARY SHARES	Weiner Ben-zion Director	Director	0 Value: $0
Aug 27, 2008 Buy	OPTIONS TO PURCHASE ORDINARY SHARES	Weiner Ben-zion Director	Director	0 Value: $0
Aug 22, 2008 Buy	OPTIONS TO PURCHASE ORDINARY SHARES	Weiss Michael S Director	Director	0 Value: $0
Aug 22, 2008 Buy	AMERICAN DEPOSITORY RECEIPTS REPRESENTING 10 ORDINARY SHARES	Weiss Michael S Director	Director	0 Value: $0
Aug 22, 2008 Buy	AMERICAN DEPOSITORY RECEIPTS REPRESENTING 10 ORDINARY SHARES	Weiss Michael S Director	Director	0 Value: $0
Aug 22, 2008 Buy	OPTIONS TO PURCHASE ORDINARY SHARES	Weiss Michael S Director	Director	0 Value: $0
Jun 10, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	48 960 Value: $158.1K
Jun 10, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	2 040 Value: $7K
Jun 10, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	2 040 Value: $7K
Jun 10, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	48 960 Value: $158.1K
Jun 09, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	32 260 Value: $108.4K
Jun 09, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	1 340 Value: $5K
Jun 09, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	1 340 Value: $5K
Jun 09, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	32 260 Value: $108.4K
Jun 06, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	96 000 Value: $329.3K
Jun 06, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	4 000 Value: $13.7K
Jun 06, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	4 000 Value: $13.7K
Jun 06, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	96 000 Value: $329.3K
Jun 05, 2008 Buy	Ordinary Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	192 000 Value: $604.8K
Jun 05, 2008 Buy	Ordinarry Shares P-Purchase	Edelman Joseph 10 Percent Owner	10% Owner	96 000 Value: $323.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCD...

Read Full Profile Here